IOncology

The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts.

ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.

At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed  antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of just 8.5%—setting new records among global studies in this space.

From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong…

Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.

At the recent 7th Tianfu Oncology Conference, Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences, delivered a keynote presentation titled “Integrative Strategies in Lung Cancer: Targeted Therapy, Immunotherapy, and ADC Management.”

With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.

In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…

A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…